Dexamethasone Treatment Options

A collection of 1455 research studies where Dexamethasone is the interventional treatment. These studies are located in the United States. Dexamethasone is used for conditions such as Multiple Myeloma, Lymphoma and Postoperative Pain.

Home

All Treatments

Dexamethasone

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Research Study

Recruiting

Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Sinusitis

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab

NCT04407442

Terminated

This phase II trial studies how well daratumumab, azacitidine, and dexamethasone work in treating patients with multiple myeloma that has come back (recurrent) or has not responded to treatment (refractory) and was previously treated with daratumumab. Daratumumab is an antibody made up of immune cells that attaches to a protein on myeloma cells, called cluster of differentiation 38 (CD38). CD38 is found in higher levels on tumor cells than on normal cells. Daratumumab prevents the growth of tumo... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/03/2024

Locations: University of California, San Francisco, San Francisco, California

Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma

Learn More ›

Surgery Prevention by Transforaminal Injection of Epidural Steroids for Cervical Radicular Pain

NCT02226159

Suspended

Cervical radicular pain is a common cause of disability and pain in the upper extremity and neck with an annual incidence of 83.2/100,000 (1). The initial treatment is conservative and includes relative rest, use of anti-inflammatory and analgesic medication, as well as physical therapy and home exercise. For patients who have persistent and significant symptoms, interventional pain management and surgical management are considered. Cervical epidural injections are the mainstay of the interventi... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/01/2024

Locations: OrthoCarolina, Charlotte, North Carolina

Conditions: Pain, Radiating

Learn More ›

Comparing the Effects of Different Doses of Dexamethasone to Treat Inpatient COVID-19

NCT04707534

Completed

This open label clinical trial is to evaluate two different doses of dexamethasone on the health outcome using World Health Organization ordinal scale at day 28 in hospitalized patients with COVID-19.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/28/2024

Locations: University of Oklahoma Medical Center, Oklahoma City, Oklahoma

Conditions: Covid19

Learn More ›

Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma

NCT01572480

Active Not Recruiting

Background: * Multiple myeloma is a blood cancer that affects the plasma cells. These cells help produce antibodies and fight infection. Smoldering multiple myeloma (SMM) is a related condition that may develop into multiple myeloma. The current standard of care for SMM is close follow-up without treatment until multiple myeloma develops. However, researchers are studying possible treatments for SMM itself. One possible treatment involves a combination of cancer treatment drugs. * Lenalidomide... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/28/2024

Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland

Conditions: Multiple Myeloma

Learn More ›

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

NCT03136146

Recruiting

This phase II trial studies the side effects and how well combination chemotherapy works in treating patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, Burkitt lymphoma/leukemia, or double-hit lymphoma/leukemia that has come back or does not respond to treatment. Drugs used in chemotherapy, such as clofarabine, etoposide, cyclophosphamide, vincristine sulfate liposome, dexamethasone and bortezomib, work in different ways to stop the growth of tumor cells, either by killing the c... Read More

Gender:

ALL

Ages:

15 years and above

Trial Updated:

03/28/2024

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia, Recurrent Burkitt Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Acute Lymphoblastic Leukemia, Refractory Burkitt Leukemia, Refractory Burkitt Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Lymphoblastic Lymphoma

Learn More ›

Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia

NCT02135874

Completed

This phase II trial studies how well clofarabine, idarubicin, cytarabine, vincristine sulfate, and dexamethasone work in treating patients with mixed phenotype acute leukemia that is newly diagnosed or has returned after a period of improvement (relapsed). Drugs used in chemotherapy, such as clofarabine, idarubicin, cytarabine, vincristine sulfate, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stop... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/20/2024

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified, Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified, Recurrent Mixed Phenotype Acute Leukemia

Learn More ›

Effectiveness of Cervical Transforaminal Epidural Steroid Injection

NCT04544683

Completed

Study Purpose: This study is intended to monitor outcomes for 1 year following cervical TFESI. Based on current clinic volume and enrollment rates into a current study of cervical epidural injections that is nearing completion, we conservatively estimate a study enrollment period of 18 months and a total period of 2.5 years from enrollment to final follow-up data collection. If the study were to theoretically start enrolling in July 2019, we would anticipate completion by February 2022. Objectives: 1. Determine the proportion of patients with an 80% or greater improvement in arm and neck numerical rating scale pain (NRS) score following an initial cervical transforaminal steroid injection (TFESI) at 4 weeks post-injection and the duration of response up to 12 months. 2. Determine the proportion of patients with a 50%-79% improvement in arm and neck NRS score following an initial cervical TFESI at 4 weeks post-injection and the duration of response up to 12 months. 3. Determine the proportion of patients with less than 50% improvement in arm and neck NRS score following an initial cervical TFESI at 4 weeks post-injection and the duration of response up to 12 months. 4. Determine the proportion of patients with an initial injection plus up to 3 additional injections that maintain 80% or greater, as well as 50-79%, improvement in arm and neck NRS score for up to 12 months. 5. Determine the proportion of patients with a clinically significant change in function defined by a minimally clinically significant change (MCIC) (≥10 point improvement ) or 30% improvement in Neck Disability Index (NDI) score following an initial cervical TFESI at 4 weeks post-injection and the duration of response up to 12 months. 6. Determine the proportion of patients with clinically significant improvement in the Medication Quantification Scale (MQS III) score (≥6.8 point change , equivalent to 10 oral morphine equivalents ) following an initial cervical TFESI at 4 weeks post-injection and the duration of response up to 12 months. 6. Determine the proportion of patients with clinically significant improvement in the categorical EuroQol 5 Dimensions tool (EQ-5D) defined by ≥0.03 following an initial cervical TFESI at 4 weeks post-injection and the duration of response up to 12 months. 7. Compare patient demographic, clinical, and imaging characteristics between response groups and perform predictive modeling to better understand variables that increase the likelihood of a successful clinical outcome. 8. Report adverse effects. Read Less

Gender:

ALL

Ages:

Between 18 years and 80 years

Trial Updated:

03/16/2024

Locations: University of Utah, Salt Lake City, Utah

Conditions: Cervical Radiculopathy, Cervical Spondylosis, Disk, Herniated

Learn More ›

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

NCT04488081

Recruiting

The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/15/2024

Locations: University of Alabama at Birmingham, Birmingham, Alabama +35 locations

University of Alabama at Birmingham, Birmingham, Alabama

UC Davis Medical Center, Davis, California

UC Irvine Medical Center, Irvine, California

Long Beach Memorial Medical Center, Long Beach, California

Kaiser LAMC, Los Angeles, California

University of Southern California, Los Angeles, California

Hoag Memorial Hospital Presbyterian, Newport Beach, California

University of California San Francisco (UCSF), San Francisco, California

University of Colorado, Aurora, Colorado

Yale Cancer Center, New Haven, Connecticut

Stamford Health, Stamford, Connecticut

Georgetown University, Washington, District of Columbia

University of Miami, Coral Gables, Florida

University of Florida, Gainesville, Florida

Emory University, Atlanta, Georgia

Northwestern University, Chicago, Illinois

University of Iowa, Iowa City, Iowa

University of Michigan, Ann Arbor, Michigan

Corewell Health, Grand Rapids, Michigan

Mercy Hospital Springfield, Springfield, Missouri

Kalispell Regional Medical Center, Kalispell, Montana

Logan Health Medical Center, Kalispell, Montana

Virtua Mount Holly Hospital, Mount Holly, New Jersey

Virtua Voorhees Hospital, Voorhees, New Jersey

Montefiore Medical Center, Bronx, New York

Columbia University Medical Center, New York, New York

University of Rochester Medical Center, Rochester, New York

Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina

University Hospital Cleveland Medical Center, Cleveland, Ohio

University of Pennsylvania (U Penn), Philadelphia, Pennsylvania

Lankenau Medical Center (Mainline Health), Wynnewood, Pennsylvania

Main Line Health - Lankenau Medical Center, Wynnewood, Pennsylvania

Sanford Health, Sioux Falls, South Dakota

DHR Health, Edinburg, Texas

University of Texas MD Anderson Cancer Center, Houston, Texas

WVU Medicine, Morgantown, West Virginia

Conditions: COVID-19

Learn More ›

Safety and Efficacy of Dexamethasone Ophthalmic Insert (Dextenza®) in the Management of Clinically Significant Dry Eye

NCT04498468

Terminated

To determine efficacy and safety profile of dexamethasone 0.4mg lacrimal insert in dry eye related ocular surface inflammation.

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

03/13/2024

Locations: Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, Maryland

Conditions: Dry Eye

Learn More ›

Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

NCT02119468

Completed

This phase I/II trial studies the side effects and best dose of ixazomib and to see how well it works when given together with pomalidomide and dexamethasone in treating patients with relapsed or relapsed/refractory multiple myeloma. Ixazomib may stop the growth of cancer by interfering with proteasomes (the protein breakdown mechanism in the cells). Pomalidomide and dexamethasone can modify and regulate the immune system and may stop cancer cells from growing. Giving ixazomib with pomalidomide... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/13/2024

Locations: Mayo Clinic, Scottsdale, Arizona +4 locations

Conditions: Refractory Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma

Learn More ›

Liposomal Bupivacaine in Shoulder Arthroscopy

NCT04461028

Withdrawn

Background: The research study is being conducted to see if using the liposomal Bupivacaine for the Interscalene block will improve the patient pain control and the whole patient's experience 48 hours after surgery when compared to using the regular Marcaine (bupivacaine hydrochloride) in addition to the dexamethasone. All preoperative, surgical, post-operative care in the recovery room, and discharge instructions will be the same as any other patient undergoing this surgery. Study procedures: 1. After obtaining informed consent, an anesthesiologist will receive an envelope with result of randomization. Patients will receive a single injection interscalene nerve block prior to surgery 2. Patients will be randomized to one of two groups: * GROUP 1 liposomal Bupivacaine - will receive a 20 ml mixture of 10 ml of Liposomal Bupivacaine 1.3% and 10 ml of Bupivacaine HCl 0.5%. * GROUP 2 Bupivacaine with dexamethasone - will receive 20 ml of Bupivacaine HCl 0.5% with 4 mg of preservative-free dexamethasone. 4. Patients will undergo general endotracheal anesthesia with inhaled anesthetic (Sevoflurane) for a goal MAC 1.0. Other than the aforementioned interscalene nerve block, patients will not receive any other local anesthetic. 5. Patients will receive a multimodal analgesic and antiemetic regimen standardized for shoulder arthroscopies at our institution. Preoperatively, all patients will receive 300 mg of gabapentin and 1,000 mg of acetaminophen orally. Intraoperatively, patients will receive 4 mg of ondansetron and 15 mg of ketorolac intravenously. Postoperatively, patients will remain on an oral regimen of 300 mg of gabapentin three times daily for one week, and 1,000 mg of acetaminophen and 10 mg of ketorolac every 8 hours for 48 hours after surgery. 6. Additional intraoperative or postoperative opioid analgesics will be administered as needed. Patients with a history of PONV or otherwise deemed high risk for PONV by the attending anesthesiologist will receive a scopolamine patch before induction of general anesthesia. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/07/2024

Locations: Penn Presbyterian Medical Center, Philadelphia, Pennsylvania

Conditions: Rotator Cuff Tears

Learn More ›

Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

NCT00381680

Completed

This randomized phase III trial is studying low-dose vincristine to see how well it works compared with high-dose vincristine when given together with different combination chemotherapy regimens in treating young patients with intermediate-risk relapsed B-cell acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giv... Read More

Gender:

ALL

Ages:

Between 1 year and 29 years

Trial Updated:

03/04/2024

Locations: Children's Hospital of Alabama, Birmingham, Alabama +172 locations

Children's Hospital of Alabama, Birmingham, Alabama

University of Alabama at Birmingham, Birmingham, Alabama

Phoenix Childrens Hospital, Phoenix, Arizona

University of Arizona Health Sciences Center, Tucson, Arizona

University of Arkansas for Medical Sciences, Little Rock, Arkansas

Children's Oncology Group, Arcadia, California

Southern California Permanente Medical Group, Downey, California

City of Hope Medical Center, Duarte, California

Loma Linda University Medical Center, Loma Linda, California

Miller Children's Hospital, Long Beach, California

Children's Hospital Los Angeles, Los Angeles, California

Cedars-Sinai Medical Center, Los Angeles, California

Children's Hospital Central California, Madera, California

Children's Hospital and Research Center at Oakland, Oakland, California

Kaiser Permanente-Oakland, Oakland, California

Childrens Hospital of Orange County, Orange, California

Lucile Packard Children's Hospital Stanford University, Palo Alto, California

Sutter General Hospital, Sacramento, California

UC Davis Comprehensive Cancer Center, Sacramento, California

Rady Children's Hospital - San Diego, San Diego, California

University of California San Francisco Medical Center-Parnassus, San Francisco, California

Santa Barbara Cottage Hospital, Santa Barbara, California

Children's Hospital Colorado, Aurora, Colorado

Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado

Connecticut Children's Medical Center, Hartford, Connecticut

Yale University, New Haven, Connecticut

Alfred I duPont Hospital for Children, Wilmington, Delaware

Children's National Medical Center, Washington, District of Columbia

Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia

Broward Health Medical Center, Fort Lauderdale, Florida

Lee Memorial Health System, Fort Myers, Florida

University of Florida, Gainesville, Florida

Nemours Children's Clinic - Jacksonville, Jacksonville, Florida

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida

Miami Children's Hospital, Miami, Florida

Baptist Hospital of Miami, Miami, Florida

Florida Hospital, Orlando, Florida

M D Anderson Cancer Center- Orlando, Orlando, Florida

Nemours Childrens Clinic - Orlando, Orlando, Florida

Nemours Children's Clinic - Pensacola, Pensacola, Florida

All Children's Hospital, Saint Petersburg, Florida

Saint Joseph Children's Hospital of Tampa, Tampa, Florida

Saint Mary's Hospital, West Palm Beach, Florida

Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia

Georgia Regents University, Augusta, Georgia

Memorial Health University Medical Center, Savannah, Georgia

University of Hawaii, Honolulu, Hawaii

Saint Luke's Mountain States Tumor Institute, Boise, Idaho

University of Illinois, Chicago, Illinois

Childrens Memorial Hospital, Chicago, Illinois

Loyola University Medical Center, Maywood, Illinois

Advocate Hope Children's Hospital, Oak Lawn, Illinois

Advocate Lutheran General Hospital, Park Ridge, Illinois

Southern Illinois University, Springfield, Illinois

Riley Hospital for Children, Indianapolis, Indiana

Saint Vincent Hospital and Health Services, Indianapolis, Indiana

Raymond Blank Children's Hospital, Des Moines, Iowa

University of Kentucky, Lexington, Kentucky

Kosair Children's Hospital, Louisville, Kentucky

Tulane University Health Sciences Center, New Orleans, Louisiana

Children's Hospital-Main Campus, New Orleans, Louisiana

Ochsner Clinic Foundation, New Orleans, Louisiana

Eastern Maine Medical Center, Bangor, Maine

Maine Children's Cancer Program, Scarborough, Maine

University of Maryland Greenebaum Cancer Center, Baltimore, Maryland

Sinai Hospital of Baltimore, Baltimore, Maryland

Johns Hopkins University, Baltimore, Maryland

Walter Reed National Military Medical Center, Bethesda, Maryland

University of Massachusetts Medical School, Worcester, Massachusetts

C S Mott Children's Hospital, Ann Arbor, Michigan

Wayne State University, Detroit, Michigan

Hurley Medical Center, Flint, Michigan

Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan

Bronson Methodist Hospital, Kalamazoo, Michigan

Kalamazoo Center for Medical Studies, Kalamazoo, Michigan

Michigan State University - Breslin Cancer Center, Lansing, Michigan

Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota

University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota

Mayo Clinic, Rochester, Minnesota

University of Mississippi Medical Center, Jackson, Mississippi

University of Missouri-Columbia, Columbia, Missouri

The Childrens Mercy Hospital, Kansas City, Missouri

Saint John's Mercy Medical Center, Saint Louis, Missouri

Children's Hospital and Medical Center of Omaha, Omaha, Nebraska

University of Nebraska Medical Center, Omaha, Nebraska

Nevada Cancer Research Foundation CCOP, Las Vegas, Nevada

Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

Hackensack University Medical Center, Hackensack, New Jersey

Saint Barnabas Medical Center, Livingston, New Jersey

Morristown Memorial Hospital, Morristown, New Jersey

Saint Peter's University Hospital, New Brunswick, New Jersey

UMDNJ - Robert Wood Johnson University Hospital, New Brunswick, New Jersey

Newark Beth Israel Medical Center, Newark, New Jersey

Saint Joseph's Regional Medical Center, Paterson, New Jersey

Overlook Hospital, Summit, New Jersey

University of New Mexico Cancer Center, Albuquerque, New Mexico

Montefiore Medical Center, Bronx, New York

Roswell Park Cancer Institute, Buffalo, New York

The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, New York

New York University Langone Medical Center, New York, New York

Mount Sinai Medical Center, New York, New York

Columbia University Medical Center, New York, New York

State University of New York Upstate Medical University, Syracuse, New York

New York Medical College, Valhalla, New York

Mission Hospitals Inc, Asheville, North Carolina

University of North Carolina, Chapel Hill, North Carolina

Carolinas Medical Center, Charlotte, North Carolina

Presbyterian Hospital, Charlotte, North Carolina

Duke University Medical Center, Durham, North Carolina

East Carolina University, Greenville, North Carolina

Wake Forest University Health Sciences, Winston-Salem, North Carolina

Children's Hospital Medical Center of Akron, Akron, Ohio

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Rainbow Babies and Childrens Hospital, Cleveland, Ohio

Cleveland Clinic Foundation, Cleveland, Ohio

Nationwide Children's Hospital, Columbus, Ohio

The Children's Medical Center of Dayton, Dayton, Ohio

Mercy Children's Hospital, Toledo, Ohio

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Legacy Emanuel Children's Hospital, Portland, Oregon

Legacy Emanuel Hospital and Health Center, Portland, Oregon

Oregon Health and Science University, Portland, Oregon

Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania

Penn State Hershey Children's Hospital, Hershey, Pennsylvania

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Saint Christopher's Hospital for Children, Philadelphia, Pennsylvania

Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania

Rhode Island Hospital, Providence, Rhode Island

Palmetto Health Richland, Columbia, South Carolina

BI-LO Charities Children's Cancer Center, Greenville, South Carolina

Greenville Cancer Treatment Center, Greenville, South Carolina

Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota

T C Thompson Children's Hospital, Chattanooga, Tennessee

East Tennessee Childrens Hospital, Knoxville, Tennessee

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

Texas Tech University Health Science Center-Amarillo, Amarillo, Texas

Dell Children's Medical Center of Central Texas, Austin, Texas

Driscoll Children's Hospital, Corpus Christi, Texas

Medical City Dallas Hospital, Dallas, Texas

University of Texas Southwestern Medical Center, Dallas, Texas

Brooke Army Medical Center, Fort Sam Houston, Texas

Cook Children's Medical Center, Fort Worth, Texas

Baylor College of Medicine, Houston, Texas

Covenant Children's Hospital, Lubbock, Texas

University of Texas Health Science Center at San Antonio, San Antonio, Texas

Methodist Children's Hospital of South Texas, San Antonio, Texas

Scott and White Memorial Hospital, Temple, Texas

Primary Children's Medical Center, Salt Lake City, Utah

University of Virginia, Charlottesville, Virginia

Childrens Hospital-King's Daughters, Norfolk, Virginia

Carilion Clinic Children's Hospital, Roanoke, Virginia

Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington

Mary Bridge Children's Hospital and Health Center, Tacoma, Washington

Madigan Army Medical Center, Tacoma, Washington

West Virginia University Charleston, Charleston, West Virginia

Saint Vincent Hospital, Green Bay, Wisconsin

University of Wisconsin Hospital and Clinics, Madison, Wisconsin

Marshfield Clinic, Marshfield, Wisconsin

Midwest Children's Cancer Center, Milwaukee, Wisconsin

Princess Margaret Hospital for Children, Perth, Western Australia

British Columbia Children's Hospital, Vancouver, British Columbia

CancerCare Manitoba, Winnipeg, Manitoba

IWK Health Centre, Halifax, Nova Scotia

McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario

Chedoke-McMaster Hospitals, Hamilton, Ontario

Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Ontario

Children's Hospital, London, Ontario

Children's Hospital of Eastern Ontario, Ottawa, Ontario

Hospital Sainte-Justine, Montreal, Quebec

Allan Blair Cancer Centre, Regina, Saskatchewan

Saskatoon Cancer Centre, Saskatoon, Saskatchewan

Swiss Pediatric Oncology Group - Bern, Bern, Not set

Swiss Pediatric Oncology Group - Lausanne, Lausanne, Not set

Conditions: B-cell Childhood Acute Lymphoblastic Leukemia, L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia

Learn More ›

Browse by State

Dexamethasone treatment options in Alabama

Dexamethasone treatment options in Alaska

Dexamethasone treatment options in Arizona

Dexamethasone treatment options in Arkansas

Dexamethasone treatment options in California

Dexamethasone treatment options in Colorado

Dexamethasone treatment options in Connecticut

Dexamethasone treatment options in Delaware

Dexamethasone treatment options in District of Columbia

Dexamethasone treatment options in Florida

Dexamethasone treatment options in Georgia

Dexamethasone treatment options in Hawaii

Dexamethasone treatment options in Idaho

Dexamethasone treatment options in Illinois

Dexamethasone treatment options in Indiana

Dexamethasone treatment options in Iowa

Dexamethasone treatment options in Kansas

Dexamethasone treatment options in Kentucky

Dexamethasone treatment options in Louisiana

Dexamethasone treatment options in Maine

Dexamethasone treatment options in Montana

Dexamethasone treatment options in Nebraska

Dexamethasone treatment options in Nevada

Dexamethasone treatment options in New Hampshire

Dexamethasone treatment options in New Jersey

Dexamethasone treatment options in New Mexico

Dexamethasone treatment options in New York

Dexamethasone treatment options in North Carolina

Dexamethasone treatment options in North Dakota

Dexamethasone treatment options in Ohio

Dexamethasone treatment options in Oklahoma

Dexamethasone treatment options in Oregon

Dexamethasone treatment options in Maryland

Dexamethasone treatment options in Massachusetts

Dexamethasone treatment options in Michigan

Dexamethasone treatment options in Minnesota

Dexamethasone treatment options in Mississippi

Dexamethasone treatment options in Missouri

Dexamethasone treatment options in Pennsylvania

Dexamethasone treatment options in Rhode Island

Dexamethasone treatment options in South Carolina

Dexamethasone treatment options in South Dakota

Dexamethasone treatment options in Tennessee

Dexamethasone treatment options in Texas

Dexamethasone treatment options in Utah

Dexamethasone treatment options in Vermont

Dexamethasone treatment options in Virginia

Dexamethasone treatment options in Washington

Dexamethasone treatment options in West Virginia

Dexamethasone treatment options in Wisconsin

Dexamethasone treatment options in Wyoming